Group issues guidelines for diagnosing, treating NAFLD and NASH
Clinicians should screen for nonalcoholic steatohepatitis in patients with hypertension, type 2 diabetes, sleep apnea, a family history of NASH, a sedentary lifestyle, obesity or hyperlipidemia, according to guidelines from the World Gastroenterology Organisation. The group also cautions against treating all nonalcoholic fatty liver disease and NASH patients aggressively, and suggests first prescribing diet and exercise. Experimental therapies may be appropriate in patients who fail to achieve adequate weight loss, the group says. Medscape (free registration)
(7/11)
Studies link moderate drinking to greater AFib risk
A study published in the Journal of the American College of Cardiology showed that even moderate daily consumption of wine or liquor, but not beer, was associated with a higher risk of developing atrial fibrillation. The risk of developing irregular heartbeat rose 8% for each additional drink of any kind of alcohol per day, an analysis of data from six studies found. HealthDay News
(7/14)
 |
Free Patient Resource Take action TODAY and visit IntheFaceofPain.com to download or order the free Handbook for People with Pain—a patient resource for those who suffer with pain.
Also available in Spanish. |
|
|
|
|
Measurement type affects dosing errors in child medications
Parents who used a teaspoon or a tablespoon to measure doses of child medication had a twofold increased risk of making a dosing error compared with those who measured the medication in milliliters, a study in the journal Pediatrics showed. Among the 287 parents included in the study, 39% made an error in measuring out the dose, while 41% made a did not know the correct prescribed dose. DailyRx.com
(7/13), HealthDay News
(7/14)
Analysis: Diabetes drug lowers dementia risk
Seniors taking the diabetes drug pioglitazone, known better by its branded name, Actos, had significantly reduced odds of dementia onset with every additional three months it was prescribed, German researchers noted. The results of the analysis were presented at the Alzheimer's Association International Conference. Reuters
(7/14)
|
| Emerging Trends, Products and Technologies |
NP's app helps identify hypertension risk in children
A free smartphone application named Pedia BP helps clinicians determine pediatric patients who are at risk of hypertension. The app has been downloaded by about 10,000 users and incorporates complex tables developed by the CDC and the National High Blood Pressure Education Program Working Group on Adolescents and Children. It is "easier to use, improves accuracy of results, simplifies the process, and saves time," said nurse practitioner Hope Bussenius, who designed the tool. Nurse.com
(7/10)
|
| Health Policy and Legislative News |
Medicaid, CHIP add 6.7M enrollees under ACA
CMS officials said Friday that 6.7 million new enrollees gained Medicaid or Children's Health Insurance Program coverage from September to May. Twenty-six states and Washington, D.C., opted to expand Medicaid, and they had a 17% increase in enrollment rates. Children are 56% of the programs' enrollees, "highlighting the importance of these programs to the health and well-being of our nation's children," said CMS Deputy Administrator Cindy Mann. The Hill
(7/11)
Conn. and Minn. reduce barriers to full practice
New laws in Connecticut and Minnesota have reduced the need for advanced practice registered nurses to have collaborative agreements. "We will continue to work as hard as we can for nurse practitioners to get the full scope authority. There is a lot of support coming from the public," AANP President Ken Miller said. NurseZone.com
(7/9)
|
CE article provides pharmacology credits
The July issue of JAANP includes a CE article on sodium glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. This new class of oral medications includes two FDA-approved drugs, dapagliflozin and canagliflozin, has a unique, insulin-independent mechanism of action and provides an alternative to other drugs in combination therapy, or as monotherapy in selected patients unable to tolerate other first-line options. The added benefits of weight loss, blood pressure reduction and improvements in lipid parameters are likely to make this new drug class a focus of intense research in the future.
|
 |
No person was ever honored for what he received. Honor has been the reward for what he gave."
-- Calvin Coolidge, 30th U.S. president
|
|
|
Please contact one of our specialists for advertising opportunities,
editorial inquiries, job placements, or any other questions.
|
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
|
|
|
